Why medspas are entering the mental health space with devices like EXOMIND

Medspas across the U.S. are beginning to blur the line between beauty and mental health care, introducing advanced brain stimulation devices like EXOMIND from Modified Wellness to their treatment menus. What began as centers focused on cosmetic rejuvenation are now evolving into wellness hubs where patients can address both external appearance and emotional well-being under one roof. This crossover reflects a powerful shift in consumer behavior—self-care is no longer just about looking better but feeling better, and that shift is pulling mental wellness technologies into spaces once reserved for facials and laser treatments.

How are medspas reframing depression treatment as part of luxury self-care?

Traditional depression care has often carried a clinical, even stigmatized aura, but medspas are reframing it as a premium self-care experience. Devices like EXOMIND use low-intensity magnetic pulses to stimulate or suppress brain activity in regions that regulate mood and cognition. The sessions are noninvasive, painless, and require no anesthesia or downtime—making them a seamless addition to the polished, spa-like setting where many clients already come for body contouring, skin tightening, or anti-aging services.

Bare Skin and Laser, for example, recently launched EXOMIND therapy as part of its medspa offerings, positioning it alongside cosmetic treatments to emphasize holistic well-being. Patients are invited to relax in private treatment rooms during their brain stimulation sessions, and the clinic markets the service as a way to enhance mood, boost motivation, and improve sleep quality without medication. This environment contrasts sharply with the sterile, clinical settings typically associated with mental health care, helping to normalize the experience and reduce stigma.

Industry analysts say this packaging matters. By framing brain stimulation as self-enhancement rather than illness treatment, medspas are attracting wellness-minded consumers who might never have sought traditional psychiatric care. The approach aligns with a broader luxury wellness trend where mental health support is being marketed as part of a lifestyle upgrade, not just a remedy for crises.

What market forces are driving medspas to diversify into brain wellness?

The business incentives are strong. The U.S. medspa market surpassed $18 billion in 2024 and is projected to grow at double-digit rates through 2030, but competition is intensifying. As more aesthetic clinics crowd the field, differentiation has become essential—and mental wellness services offer a compelling new niche with high margins and rising demand. The global market for noninvasive brain stimulation devices, meanwhile, is projected to exceed $16 billion by 2030, driven largely by expanding use in depression care.

Offering EXOMIND also allows medspas to reach a different demographic segment: clients seeking relief from burnout, stress, or low mood rather than cosmetic enhancement. This can boost foot traffic during off-peak aesthetic cycles and create subscription-style recurring revenue through multi-session treatment packages. Clinics like Bare Skin and Laser have bundled EXOMIND therapy with other wellness services, encouraging patients to view mental and physical optimization as complementary goals.

There is also a branding advantage. By adopting cutting-edge neurotech, medspas can position themselves as forward-thinking wellness innovators, not just beauty boutiques. That reputational shift could be critical as younger consumers, especially millennials and Gen Z, place higher value on mental health support and are more likely to pay out of pocket for holistic wellness services.

Could medspas reshape public perceptions of brain stimulation therapies?

While brain stimulation has been clinically validated for depression treatment, public awareness remains limited—and misconceptions persist. Some people still associate all brain stimulation with electroconvulsive therapy (ECT), a high-intensity hospital procedure used only for severe cases under anesthesia. By contrast, EXOMIND delivers gentle, focused pulses similar to those used in transcranial magnetic stimulation (TMS) but with a more streamlined protocol suitable for outpatient settings.

Medspas are uniquely positioned to change these perceptions. Their emphasis on comfort, relaxation, and aesthetic appeal can help make brain stimulation approachable, presenting it as an accessible tool for boosting mood and resilience rather than a last-resort medical intervention. If early adopters report positive experiences, this could generate word-of-mouth momentum and normalize neuromodulation as part of routine wellness care.

That cultural shift could ripple back into the broader healthcare ecosystem, expanding the pool of patients open to trying drug-free depression therapies. In effect, medspas could become an unexpected on-ramp to mental health support, introducing people to technologies like EXOMIND who might otherwise avoid or delay treatment through traditional channels.